+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection

Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection

Journal of Infectious Diseases 205(7): 1147-1154

Chikungunya virus (CHIKV) and related arboviruses have been responsible for large epidemic outbreaks with serious economic and social impact. Although infected individuals clear the virus from the blood, some develop debilitating and prolonged arthralgia. We investigated specificity and strength of antibody responses in a longitudinal study on CHIKV-infected patients and analyzed their association with viral load, cytokine profile, and severity. We found that CHIKV-specific response is dominated by immunoglobulin G3 (IgG3) antibodies. The antibodies were neutralizing, and patients with high viremia rapidly developed high levels of anti-CHIKV antibodies of this specific isotype. Although these patients endured a more severe disease progression during the acute viremic phase, they cleared the virus faster and did not experience persistent arthralgia. However, significant persistent arthralgia was observed in patients with low viremia who developed IgG3 at a later stage. Absence of early CHIKV-specific IgG3 may therefore serve as a specific marker of patients with increased risk of disease.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052755209

Download citation: RISBibTeXText

PMID: 22389226

DOI: 10.1093/infdis/jis033

Related references

Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice. Journal of Virology 72(3): 2253-2258, 1998

Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand. Virology Journal 11: 183, 2014

Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. Journal of Hepatology 71(1): 14-24, 2019

Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 366(1): 166-173, 2007

Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. Journal of Infectious Diseases 205(5): 763-771, 2012

Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without viral clearance. Journal of Viral Hepatitis 18(6): 424-433, 2011

Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clinical and Diagnostic Laboratory Immunology 2(3): 302-306, 1995

Enhanced virus clearance and prevention of CTL exhaustion by early inducible lymphocytic choriomeningitis virus specific neutralizing antibodies. Immunology Letters 56(Part-P1): 26-27, 1997

Immune protection against foot-and-mouth disease virus studied using virus-neutralizing and non-neutralizing concentrations of monoclonal antibodies. Immunology 58(3): 421-428, 1986

Long term follow up of immunoglobulin g and immunoglobulin a antibodies against viral capsid antigens of epstein barr virus in nasopharyngeal carcinoma. Journal of Laryngology & Otology 99(6): 567-572, 1985

Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane. Cell Host and Microbe 24(3): 417-428.E5, 2018

Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice. Virus Research 167(2): 236-246, 2012

The neutralizing role of IgM during early Chikungunya virus infection. Plos one 12(2): E0171989, 2017

Neutralizing Antibodies from Convalescent Chikungunya Virus Patients Can Cross-Neutralize Mayaro and Una Viruses. American Journal of Tropical Medicine and Hygiene 100(6): 1541-1544, 2019

Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model. Clinical Immunology 149(3): 487-497, 2013